Overview

LL-37 is a 37-amino-acid human cathelicidin antimicrobial peptide generated from the C-terminal region of the hCAP18 precursor protein encoded by the CAMP gene. It is one of the most widely studied human host-defense peptides because it sits at the intersection of innate immunity, microbial defense, epithelial biology, inflammatory signaling, chemotaxis, wound-repair research, and barrier-tissue homeostasis.

In laboratory settings, LL-37 is studied for direct antimicrobial activity, membrane interactions, anti-biofilm effects, immune-cell modulation, epithelial-cell migration, angiogenesis-related signaling, and its ability to bind nucleic acids and other negatively charged biological molecules. Its biology is complex: depending on concentration, tissue context, local proteases, microbial burden, and inflammatory state, LL-37 may appear protective, regulatory, pro-inflammatory, or potentially pathogenic.

Quick Reference

Discovery and Cathelicidin Biology

Cathelicidins are a family of host-defense molecules found across many species. Humans express one major cathelicidin precursor, hCAP18, which can be proteolytically processed to generate LL-37. The mature peptide is named for its first two leucine residues and its 37-amino-acid length.

LL-37 is produced by multiple cell types relevant to barrier defense and immune surveillance, including neutrophils, epithelial cells, keratinocytes, macrophages, and cells in mucosal tissues. Expression can be influenced by infection, tissue injury, inflammatory mediators, vitamin D-related signaling, microbial products, and epithelial stress.

The peptide is frequently studied in skin, lung, gastrointestinal, oral, urinary, and wound models because these tissues are exposed to microbes and rely heavily on innate defense mechanisms. LL-37 research therefore spans microbiology, immunology, dermatology, wound biology, and host-pathogen interaction studies.

Molecular Structure

LL-37 is a cationic and amphipathic peptide, meaning that it contains positively charged regions and both hydrophobic and hydrophilic surfaces. These properties help explain why LL-37 can interact with negatively charged bacterial membranes, microbial components, nucleic acids, extracellular matrix molecules, and host-cell membranes.

In solution, LL-37 can adopt alpha-helical structure under membrane-like conditions. Its conformational flexibility is important because its biological behavior depends on environment, ionic strength, pH, peptide concentration, lipid composition, protease exposure, and binding partners.

Because LL-37 is short, highly charged, and biologically active in multiple systems, analytical identity and purity are especially important in laboratory contexts. Deletion sequences, truncation products, oxidation products, salt-form differences, and synthesis-related impurities may affect reproducibility in cell, microbial, and tissue models.

Mechanism and Cellular Signaling

Direct antimicrobial mechanisms

LL-37 is often studied for broad antimicrobial activity against bacteria and selected fungi and viruses in experimental systems. A major proposed mechanism involves binding to microbial membranes, altering membrane integrity, and disrupting microbial viability. The peptide’s positive charge allows interaction with negatively charged microbial surfaces, while amphipathic structure supports membrane insertion or destabilization.

Direct killing activity is not uniform across organisms or conditions. Salt concentration, serum proteins, wound fluid, pH, microbial growth phase, biofilm status, and local proteases may change observed potency. For this reason, LL-37 antimicrobial results should be interpreted in the context of assay design rather than generalized across all microbes.

Biofilm research

Biofilms are organized microbial communities embedded in extracellular matrix material. They can show altered susceptibility to antimicrobials and immune clearance. LL-37 has been investigated for anti-biofilm activity, including effects on microbial attachment, biofilm formation, biofilm architecture, and bacterial signaling pathways.

Anti-biofilm findings are scientifically important because chronic wounds, device-associated infections, dental plaque, and mucosal infections often involve biofilm-like microbial communities. However, biofilm assays vary substantially, and in vitro disruption of a biofilm does not automatically establish clinical efficacy.

Immunomodulatory signaling

LL-37 can modulate immune signaling beyond direct microbe killing. It has been studied in relation to neutrophils, monocytes, macrophages, dendritic cells, T cells, epithelial cells, mast cells, and chemotactic responses. Depending on the model, LL-37 may influence cytokine release, chemokine signaling, immune-cell recruitment, inflammatory resolution, and pathogen recognition pathways.

One of the most important interpretive points is that LL-37 can appear anti-inflammatory in some settings and pro-inflammatory in others. It may neutralize certain microbial inflammatory triggers, while also amplifying immune activation when complexed with nucleic acids or when present in inflamed tissue.

Nucleic-acid complexes and toll-like receptor signaling

LL-37 can bind self-DNA and self-RNA, forming complexes that may protect nucleic acids from degradation and promote uptake by immune cells. These complexes have been studied in relation to toll-like receptor signaling, plasmacytoid dendritic-cell activation, type I interferon production, and autoimmune skin inflammation.

This mechanism is especially relevant to psoriasis and lupus-related research, where LL-37 has been proposed to contribute to inappropriate immune recognition of self-derived nucleic acids. In this context, LL-37 is not simply protective; it may participate in inflammatory amplification.

Wound-Repair and Tissue-Regeneration Models

LL-37 is frequently studied in wound-repair models because it may influence several processes relevant to tissue closure, including keratinocyte migration, epithelial proliferation, angiogenesis-related signaling, immune-cell recruitment, and microbial burden. This makes it a biologically attractive research tool for studying the overlap between barrier defense and repair.

Experimental wound models have reported effects on re-epithelialization, granulation-tissue formation, endothelial-cell behavior, and infected-wound outcomes. Some clinical research has evaluated topical LL-37 approaches in hard-to-heal wounds, including venous leg ulcers and diabetic foot ulcer contexts, but these findings should be described as investigational and condition-specific rather than generalized.

Wound healing is complex and depends on blood flow, immune status, microbial load, extracellular matrix remodeling, oxygenation, nutrition, mechanical stress, and comorbid disease. LL-37 research may help clarify specific pathways in repair biology, but it should not be presented as a universal wound-healing solution.

Skin Biology and Dermatology Research

Skin is one of the central areas of LL-37 research because keratinocytes can produce cathelicidin and because the skin barrier is constantly exposed to microbes, injury, and inflammatory triggers. LL-37 has been studied in antimicrobial defense, barrier repair, rosacea, atopic dermatitis, psoriasis, and wound-related skin models.

In psoriasis research, LL-37 has received particular attention because it can bind self-DNA or self-RNA and may promote immune recognition of self-derived nucleic acids. LL-37-specific T-cell responses have also been described in psoriasis studies, supporting the idea that LL-37 can participate in both innate and adaptive immune activation under certain conditions.

In rosacea-related research, abnormal processing or increased expression of cathelicidin peptides has been linked to inflammatory skin responses. These findings reinforce the importance of context: elevated or dysregulated LL-37-related signaling may contribute to inflammation even though cathelicidin peptides are part of normal host defense.

Mucosal Immunity Research

LL-37 is studied in mucosal tissues including the respiratory tract, oral cavity, gastrointestinal tract, urinary tract, and reproductive tract. These sites require continuous balancing between microbial defense, tolerance of commensal organisms, epithelial integrity, and inflammatory control.

Respiratory models have investigated LL-37 in airway epithelial repair, microbial defense, viral-response research, and inflammatory lung conditions. Oral and periodontal studies have examined LL-37 in gingival inflammation, microbial communities, and epithelial defense. Gastrointestinal studies have explored barrier function, microbial interactions, and inflammatory signaling.

Because mucosal surfaces differ in pH, salt concentration, mucus composition, protease activity, microbiome structure, and epithelial turnover, findings from one tissue model should not be assumed to apply directly to another.

Infection and Host-Pathogen Research

LL-37 has been evaluated against a range of pathogens in cell culture, microbial assays, animal models, and translational studies. Research includes Gram-positive and Gram-negative bacteria, biofilm-forming organisms, fungi, enveloped viruses, and polymicrobial wound models.

The peptide is also studied as part of the host response rather than only as an isolated antimicrobial molecule. In vivo, LL-37 may influence immune-cell recruitment, epithelial barrier repair, endotoxin responses, and the balance between pathogen control and tissue-damaging inflammation.

Translation remains challenging. Peptide degradation, serum binding, local toxicity, concentration-dependent host-cell effects, manufacturing consistency, delivery method, and tissue exposure all affect whether antimicrobial activity seen in vitro can be reproduced in more complex biological systems.

Inflammation and Autoimmune Pathway Research

LL-37 research is highly relevant to inflammation because the peptide can shape cytokine signaling, immune-cell activation, and danger-signal recognition. It may dampen some microbial-triggered responses while amplifying others, particularly when bound to nucleic acids or present in chronically inflamed tissue.

Autoimmune and inflammatory disease models are among the most important areas where LL-37 requires careful wording. In psoriasis and lupus-related research, LL-37-nucleic-acid complexes have been associated with interferon-driven immune activation. These pathways are scientifically important but do not support simplistic claims that LL-37 is uniformly “immune boosting.”

A balanced research guide should present LL-37 as an immunologically active peptide with both protective and potentially inflammatory roles depending on biological context.

Cancer Biology Research

LL-37 has been investigated in cancer biology, but findings are highly tissue- and model-dependent. Some studies suggest that LL-37-related signaling may influence tumor-cell proliferation, migration, angiogenesis, immune microenvironment behavior, or epithelial transformation. Other studies have proposed context-specific tumor-suppressive associations.

This mixed literature should be handled cautiously. Cancer models differ by tissue origin, receptor expression, inflammatory environment, peptide concentration, and experimental endpoint. LL-37 should not be represented as a cancer therapy or cancer-prevention agent. It is best described as a research molecule involved in host-defense and inflammatory pathways that may intersect with tumor biology in specific experimental contexts.

Animal Studies

Animal studies have explored LL-37 or LL-37-derived peptides in wound repair, infected wounds, sepsis models, lung injury, skin inflammation, biofilm-associated infection, and mucosal defense. These studies are useful because they allow researchers to examine tissue exposure, microbial challenge, immune response, and repair outcomes in whole-organism systems.

Interpretation is complicated by species differences. Humans express LL-37 from hCAP18, while common rodent models rely on related but distinct cathelicidin biology. Researchers may use human LL-37 directly, LL-37 analogs, transgenic models, or species-specific orthologs, and each design has different translational limitations.

Human Research and Clinical Evidence

Human evidence includes observational studies measuring LL-37 or cathelicidin expression in disease states, ex vivo immune-cell studies, wound-fluid analyses, skin-biopsy research, biomarker studies, and limited interventional research involving topical LL-37-based approaches. Compared with the broad mechanistic literature, completed clinical evidence remains limited and context-specific.

Clinical wound research is one of the more developed translational areas. Trials and prospective studies have evaluated topical LL-37 preparations or LL-37-containing approaches in selected wound populations, including hard-to-heal ulcers and infected wound contexts. These studies are informative but should not be generalized to systemic use, non-wound applications, or untested populations.

Observational human studies can show that LL-37 expression is elevated, reduced, or dysregulated in particular conditions, but they do not prove that adding LL-37 will improve outcomes. In many inflammatory disorders, increased LL-37 may be part of the disease process rather than a simple deficiency marker.

Research Limitations

LL-37 research has several important limitations. First, in vitro antimicrobial potency may not translate to tissue settings because serum proteins, salts, proteases, wound fluid, and host-cell interactions can alter activity. Second, LL-37 can be degraded or modified by local proteases. Third, peptide concentration can determine whether a response is antimicrobial, immunomodulatory, cytotoxic, or inflammatory.

Fourth, LL-37 biology varies by tissue. Skin, airway, oral mucosa, wounds, and gastrointestinal models differ substantially. Fifth, immune outcomes depend heavily on whether LL-37 is free, membrane-bound, complexed with nucleic acids, bound to microbial products, or processed into shorter fragments. Sixth, long-term human safety and pharmacokinetic data are limited outside specific investigational settings.

For publication-quality educational content, LL-37 should be framed as a research peptide with diverse host-defense functions and meaningful translational challenges, not as a simple antimicrobial replacement or broad immune-enhancing product.

Analytical Testing

HPLC purity

High-performance liquid chromatography is commonly used to estimate peptide purity. A chromatogram separates detected components under defined method conditions. The main peak represents the dominant detected component, while smaller peaks may represent related impurities, incomplete sequences, truncation products, oxidation products, synthesis byproducts, or degradation products.

For LL-37, purity assessment is especially relevant because peptide charge, hydrophobicity, aggregation tendency, and container adsorption can affect experimental behavior. HPLC purity should be interpreted alongside identity confirmation and batch-specific documentation.

Mass confirmation

Mass spectrometry, including LC-MS or MALDI-based methods, may be used to compare observed molecular mass with the expected mass of LL-37. Mass confirmation supports identity but does not by itself prove purity, sterility, endotoxin status, biological activity, or suitability for any specific experimental model.

COA interpretation

A batch-specific Certificate of Analysis should identify the compound name, lot number, analytical method, purity result, identity-confirmation method when available, appearance, testing date, and storage recommendations. For immune or microbial assays, researchers may also consider endotoxin testing, solvent compatibility, and laboratory-specific validation.

Purity Standards and Research Documentation

For laboratory research, documentation should be clear, lot-specific, and traceable. Researchers commonly review HPLC purity, mass confirmation, appearance, storage history, reconstitution records, solvent system, concentration, aliquoting procedure, freeze-thaw history, and any deviations from standard procedure.

Because LL-37 can interact with membranes, nucleic acids, proteins, plastics, salts, and microbial components, experimental reproducibility depends on both compound quality and method consistency. Assay conditions such as serum percentage, ionic strength, culture medium, microbial growth phase, and exposure duration should be documented carefully.

Stability and Laboratory Handling

Research peptides are commonly supplied as lyophilized powders because reduced water content can improve storage stability. Peptide integrity may still be affected by temperature, moisture, oxygen exposure, light, pH, concentration, protease contamination, and repeated freeze-thaw cycling.

General laboratory handling principles include minimizing moisture exposure, using clean technique, protecting material from unnecessary heat and light, avoiding repeated freeze-thaw cycles when possible, keeping clear batch records, and following validated internal procedures for preparation and storage.

Once a peptide is dissolved, stability may differ from lyophilized stability. Solution-phase LL-37 may be vulnerable to hydrolysis, oxidation, adsorption to container surfaces, aggregation, microbial contamination, and concentration-dependent loss. Research groups should validate storage and handling conditions for their specific assay system.

Frequently Asked Questions

What is LL-37?

LL-37 is a 37-amino-acid human cathelicidin-derived host-defense peptide generated from the hCAP18 precursor protein and studied for antimicrobial, immunomodulatory, epithelial, wound-repair, and inflammatory signaling roles.

Is LL-37 the only human cathelicidin antimicrobial peptide?

LL-37 is widely described as the only human cathelicidin-derived antimicrobial peptide generated from the hCAP18 precursor, although related fragments and processed forms can appear in specific tissues or inflammatory settings.

What pathways are most associated with LL-37 research?

LL-37 is most often associated with microbial membrane disruption, biofilm modulation, epithelial migration, chemotaxis, cytokine signaling, toll-like receptor pathways, nucleic-acid-complex signaling, and inflammatory skin biology.

Is LL-37 only antimicrobial?

No. LL-37 is antimicrobial, but it is also immunomodulatory. It can influence immune-cell recruitment, epithelial repair, cytokine responses, nucleic-acid sensing, and inflammatory signaling depending on context.

Does LL-37 have human clinical trial evidence?

Human interventional evidence remains limited and is most developed in selected topical wound-research contexts. LL-37 should not be described as having established broad clinical efficacy.

Is LL-37 approved for medical use?

This page does not present LL-37 as approved for human or veterinary use. It is discussed only as a research compound for educational and laboratory contexts.

What analytical testing is relevant for LL-37?

Common research documentation may include HPLC purity analysis, mass spectrometry identity confirmation, batch-specific COA information, appearance, endotoxin considerations for immune assays, lot traceability, and storage documentation.

Is this medical advice?

No. This page is educational content for laboratory research contexts only and does not provide medical advice, dosing guidance, treatment recommendations, or administration instructions.

References and Further Reading

• Ridyard KE, Overhage J. The potential of human peptide LL-37 as an antimicrobial and anti-biofilm agent. Antibiotics. 2021.
• Duplantier AJ, van Hoek ML. The human cathelicidin antimicrobial peptide LL-37 as a potential treatment for polymicrobial infected wounds. Frontiers in Immunology. 2013.
• Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cellular Immunology. 2012.
• Xhindoli D et al. The human cathelicidin LL-37: a pore-forming antibacterial peptide and host-cell modulator. Biochimica et Biophysica Acta. 2016.
• Kahlenberg JM, Kaplan MJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. Journal of Immunology. 2013.
• Morizane S et al. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. Journal of Investigative Dermatology. 2012.
• Lande R et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nature Communications. 2014.
• Ramos R et al. Wound healing activity of the human antimicrobial peptide LL37. Peptides. 2011.
• Grönberg A et al. Stability of the cathelicidin peptide LL-37 in a non-healing wound environment. Acta Dermato-Venereologica. 2011.
• Simonetti O et al. Efficacy of cathelicidin LL-37 in an MRSA wound infection mouse model. Antibiotics. 2021.
• Miranda E et al. Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcers. Archives of Dermatological Research. 2023.
• Pahar B et al. Immunomodulatory role of the antimicrobial LL-37 peptide in autoimmune diseases and viral infections. Vaccines. 2020.